BCIQ Profiles

Company Profile Report

Barvarian Nordic's smallpox vaccine meets in Phase III

Bavarian Nordic A/S (CSE:BAVA) reported data from an open-label Phase III trial showing that its Imvamune smallpox vaccine met the co-primary endpoints of non-inferiority to ACAM2000, an FDA-approved, second-generation smallpox vaccine from

Read the full 328 word article

How to gain access

Continue reading with a
two-week free trial.